A pharmacovigilance team is evaluating the time to adverse event onset (measured in discrete whole days) for a newly approved biologic medication in a post-marketing surveillance registry of patients. The initial dataset has a heavily right-skewed distribution, and the team calculates the following summary statistics:
- Mean: days
- Median: days
- Mode: days (accounting for of patients)
- Standard Deviation: days
- 75th percentile: days
For a standardized regulatory safety report, the team creates a revised dataset by recoding any time to onset exceeding days as exactly days. A review of the initial data reveals that of the patients had a time to onset strictly greater than days.
Which of the following best describes the expected changes to the mode, median, mean, and standard deviation in the revised dataset compared to the initial dataset?
- The mode will increase; the mean and standard deviation will decrease; the median will remain unchangedAnswer
- BThe mean and standard deviation will decrease; the mode and median will remain unchanged
- CThe mean, median, and standard deviation will decrease; the mode will remain unchanged
- DThe median and mode will increase; the mean and standard deviation will decrease
- EThe mean, median, standard deviation, and mode will all decrease